Core Viewpoint - RAPT Therapeutics, Inc. is actively engaging with investors through participation in multiple healthcare conferences in March 2025, highlighting its focus on immunology-based therapies for inflammatory and immunological diseases [1][3]. Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapies aimed at treating patients with inflammatory and immunological diseases [2]. - The company leverages proprietary expertise in immunology to create therapies that modulate critical immune responses associated with these diseases [2]. Upcoming Events - RAPT Therapeutics will participate in the Leerink Global Healthcare Conference with a fireside chat scheduled for March 11, 2025, at 3:40 p.m. ET [3]. - The company will also take part in the Barclays 27th Annual Global Healthcare Conference, with a fireside chat on March 12, 2025, at 10:30 a.m. ET [3].

Company Overview - Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence and smoking cessation [3] - The company has successfully completed two Phase 3 studies for smoking cessation and one Phase 2 study for vaping cessation, with plans to submit a new drug application in Q2 2025 [3][6] Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aimed at reducing nicotine cravings and the satisfaction associated with nicotine products [6] - Approximately 29 million adults smoke combustible cigarettes in the U.S., with tobacco use being the leading cause of preventable death, responsible for over 8 million deaths globally and nearly half a million in the U.S. annually [4] - There are over 11 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a critical need that cytisinicline aims to address [5] Upcoming Events - Achieve Life Sciences will present at the Barclays 27th Annual Global Healthcare Conference from March 11-13, 2025, with CEO Rick Stewart scheduled to present on March 12, 2025 [1][2]

Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, utilizing misfolded proteins as a target [3] - The company has two clinically validated technology platforms, SupraAntigen and Morphomer, which support a diverse pipeline of sixteen therapeutic and diagnostic programs, with five in Phase 2 and one in Phase 3 development [3] - AC Immune has established strategic partnerships with leading global pharmaceutical companies, resulting in over $4.5 billion in potential milestone payments and royalties [3] Upcoming Events - AC Immune management will participate in the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 11, 2025 [6]

Company Overview - Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with over 120 years of commitment to improving health, operating in 57 markets with a workforce of 37,000 employees [2] Upcoming Events - Richard Francis, Teva's President and CEO, will present at two investor conferences in March 2025: Barclays 27th Annual Global Healthcare Conference on March 11 at 8:00 am ET and Leerink Partners Global Healthcare Conference on March 12 at 8:40 am ET [1][4] Investor Relations - A live webcast of the presentations will be available on Teva's Investor Relations website, with an archived version accessible within 24 hours after the live discussion [1]